Author

Huiwen Deng 1

1 AbbVie Inc., North Chicago, United States

BENEFITS OF HIGH VERSUS LOW DOSE UPADACITINIB AS MAINTENANCE TREATMENT IN ULCERATIVE COLITIS PATIENTS WHO WERE RESPONDERS TO 8-WEEK INDUCTION WITH UPADACITINIB: RESULTS FROM THE U-ACHIEVE PHASE 3 MAINTENANCE TRIAL

Brian G. Feagan, Gareth Parkes, Pascal Juillerat, Krisztina Barbara Gecse, Xuan Yao, Wen Zhou, Huiwen Deng, Dapo Ilo, Yuri Sanchez Gonzalez, Peter D.R. Higgins

FATIGUE IMPROVEMENT CORRELATES WITH REDUCTIONS IN WORK PRODUCTIVITY IMPAIRMENT AND RELATED INDIRECT COST IN PATIENTS WITH CROHN’S DISEASE: POST HOC ANALYSIS OF PHASE 3 RISANKIZUMAB INDUCTION TRIALS

Edouard Louis, Julian Panés, Subrata Ghosh, Britta Siegmund, Wan-Ju Lee, Huiwen Deng, Kristina Kligys, Jasmina Kalabic, Edward V. Loftus

MATCHING-ADJUSTED INDIRECT COMPARISONOF UPADACITINIB VERSUS VEDOLIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Walter Reinisch, Severine Vermeire, Charlotte Hedin, David T. Rubin, Julian Panés, Huiwen Deng, Si Xuan, Lani Wegrzyn, John Liu, Dapo Ilo, Wen Zhou, Yuri Sanchez Gonzalez, Remo Panaccione

Item 1 - 3 / 3
1